Cargando…
TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells
INTRODUCTION: Tumor invasion and metastasis remain a major cause of mortality in breast cancer patients. High concentrations of nitric oxide (NO) suppress tumor invasion and metastasis in vivo. NO prodrugs generate large amounts of NO upon metabolism by appropriate intracellular enzymes, and therefo...
Autores principales: | Simeone, Ann-Marie, McMurtry, Vanity, Nieves-Alicea, René, Saavedra, Joseph E, Keefer, Larry K, Johnson, Marcella M, Tari, Ana M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2481491/ https://www.ncbi.nlm.nih.gov/pubmed/18474097 http://dx.doi.org/10.1186/bcr2095 |
Ejemplares similares
-
Role of human glutathione transferases in biotransformation of the nitric oxide prodrug JS-K
por: Sjödin, Birgitta, et al.
Publicado: (2021) -
Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance()
por: Maciag, Anna E., et al.
Publicado: (2013) -
JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells
por: Laschak, Martin, et al.
Publicado: (2012) -
Nitric oxide released from JS-K induces cell death by mitotic catastrophe as part of necrosis in glioblastoma multiforme
por: Günzle, Jessica, et al.
Publicado: (2016) -
JS-K, a Nitric Oxide Prodrug, Has Enhanced Cytotoxicity in Colon Cancer Cells with Knockdown of Thioredoxin Reductase 1
por: Edes, Kornelia, et al.
Publicado: (2010)